We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

DIAGAST

DIAGAST develops, manufactures and markets reagents and automated systems for blood group determination. Its wide pro... read more Featured Products: More products

Download Mobile App





Diagast Presents Latest Immunohaematology Solutions at MEDLAB Middle East

By LabMedica International staff writers
Posted on 26 Jan 2022
Print article
Image: DIAGAST at MEDLAB Middle East (Photo courtesy of DIAGAST)
Image: DIAGAST at MEDLAB Middle East (Photo courtesy of DIAGAST)

DIAGAST (Loos, France) participated in the 2022 edition of MEDLAB Middle East held at the Dubai World Trade Centre (DWTC) from January 24 to 27 where it presented its latest immunohaematology solutions and also organized a scientific workshop for Blood Transfusion Day.

Blood transfusion is at the heart of healthcare professionals’ concerns. From the donor to the patient, there are many challenges to be met to ensure the compatibility of transfusions. DIAGAST is a worldwide leader in the marketing and development of reagents and instrumentation systems that aim to ensure donor and patient compatibility during blood transfusions. The company develops, manufactures and markets reagents (for blood group determination), miniaturized laboratories for manual analysis and automated systems. DIAGAST offers high performance product ranges and automated systems, guaranteeing the quality of transfusion diagnosis and patient safety.

At MEDLAB Middle East 2022, DIAGAST showcased its QWALYS 3 EVO automated system which is the only fully-automated system on the market using the magnetization of erythrocytes, a process that no longer requires washing and centrifugation steps. DIAGAST’s Erythrocyte Magnetized (EM) technology is based on Red Blood Cells (RBC) magnetization. This innovative solution enables avoiding washing and centrifugation steps usually associated to traditional immunohaematology testing. It uses a patented high-density solution (NanoLys) which creates a barrier that blocks non-specific antibodies which could interfere when performing direct and indirect antiglobulin tests. A latest-generation and fully-automated system with high throughput, large loading capacity and STAT function among others, QWALYS 3 EVO is the benchmark instrument for all laboratories, blood banks, blood transfusion centers and hospitals.

Related Links:
DIAGAST 

New
Gold Supplier
SARS-CoV-2 Assay
INgezim COVID 19 SPIKE CROM
New
Automated Hematology Workstation
XN-3000
New
Whole Blood Control
ESR-Chex Plus
New
POC Pathogen Detection & Gene Expression System
Sal6830 Mobile Workstation

Print article
IIR Middle East

Channels

Molecular Diagnostics

view channel
Image: Metabolomic profiling reveals risk of multiple diseases all at once (Photo courtesy of BIH)

Single Blood Test Predicts Risk of Multiple Diseases Simultaneously Using AI

Prevention is better than cure. To prevent diseases from occurring in the first place, it is important to identify those individuals who are at particularly high risk as early as possible.... Read more

Technology

view channel
Image: OneDraw Blood Collection Device significantly reduces obstacles for drawing blood (Photo courtesy of Drawbridge Health)

Near Pain-Free Blood Collection Technology Enables High-Quality Testing

Blood tests help doctors diagnose diseases and conditions such as cancer, diabetes, anemia, and coronary heart disease, as well as evaluate organ functionality. They can also be used to identify disease... Read more

Industry

view channel
Image: The global infectious disease IVD market is expected to hit USD 57 billion by 2030 (Photo courtesy of Pexels)

Global Infectious Disease IVD Market Dominated by Molecular Diagnostics Technology

The global infectious disease in vitro diagnostics (IVD) market stood at USD 113.7 billion in 2021 and is expected to grow at a CAGR of -7.41% from 2022 to 2030 to hit around USD 56.89 billion by 2030,... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.